144 related articles for article (PubMed ID: 24505530)
1. Immunohistochemical Analysis of p53, Ki-67, CD44, HER-2/neu Expression Patterns in Gastric Cancer, and Their Association with One Year Survival in North-West of Iran.
Sanaat Z; Halimi M; Ghojezadeh M; Pirovi AH; Gharamaleki JV; Ziae AE; Kermani IA
Int J Hematol Oncol Stem Cell Res; 2013; 7(3):15-20. PubMed ID: 24505530
[TBL] [Abstract][Full Text] [Related]
2. The Expression of p53, CD44, Ki-67, and HER-2/neu Markers in Gastric Cancer and Its Association with Histopathological Indicators: A Retrospective Study.
Ahadi M; Moradi A; Musavinejad L; Movafagh A; Moradi A
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1607-1614. PubMed ID: 32592354
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma.
Ahmed A; Al-Tamimi DM
Libyan J Med; 2018 Dec; 13(1):1466573. PubMed ID: 29697008
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: correlation with clinical outcome.
Amir G; Issakov J; Meller I; Sucher E; Peyser A; Cohen IJ; Yaniv I; Ben Arush MW; Tavori U; Kollender Y; Ron N; Peylan-Ramu N
Hum Pathol; 2002 Feb; 33(2):170-4. PubMed ID: 11957141
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
Sawaki M; Ito Y; Akiyama F; Tokudome N; Horii R; Mizunuma N; Takahashi S; Horikoshi N; Imai T; Nakao A; Kasumi F; Sakamoto G; Hatake K
Breast Cancer; 2006; 13(2):172-8. PubMed ID: 16755113
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
Wang Y; Zhang XR; Fu J; Tan W; Zhang W
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.
Marks JR; Humphrey PA; Wu K; Berry D; Bandarenko N; Kerns BJ; Iglehart JD
Ann Surg; 1994 Apr; 219(4):332-41. PubMed ID: 7909221
[TBL] [Abstract][Full Text] [Related]
9. Clinico-Pathological and Prognostic Significance of p53, Bcl-2 and Her-2/neu Protein Markers in Colorectal Cancer Using Tissue Microarray.
Ismail HM; El-Baradie M; Moneer M; Khorshid O; Touny A
J Egypt Natl Canc Inst; 2007 Mar; 19(1):3-14. PubMed ID: 18839030
[TBL] [Abstract][Full Text] [Related]
10. Effect of Hydrochloric Acid Decalcification on Expression Pattern of Prognostic Markers in Invasive Breast Carcinomas.
Maclary SC; Mohanty SK; Bose S; Chung F; Balzer BL
Appl Immunohistochem Mol Morphol; 2017 Feb; 25(2):144-149. PubMed ID: 27028239
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients.
Al-Moundhri MS; Nirmala V; Al-Hadabi I; Al-Mawaly K; Burney I; Al-Nabhani M; Thomas V; Ganguly SS; Grant C
J Surg Oncol; 2005 Sep; 91(4):243-52. PubMed ID: 16121348
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial DNA alterations correlate with the pathological status and the immunological ER, PR, HER-2/neu, p53 and Ki-67 expression in breast invasive ductal carcinoma.
Lin CS; Chang SC; Ou LH; Chen CM; Hsieh SS; Chung YP; King KL; Lin SL; Wei YH
Oncol Rep; 2015 Jun; 33(6):2924-34. PubMed ID: 25845386
[TBL] [Abstract][Full Text] [Related]
13. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
Maru D; Middleton LP; Wang S; Valero V; Sahin A
Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
Learn PA; Yeh IT; McNutt M; Chisholm GB; Pollock BH; Rousseau DL; Sharkey FE; Cruz AB; Kahlenberg MS
Cancer; 2005 Jun; 103(11):2252-60. PubMed ID: 15834928
[TBL] [Abstract][Full Text] [Related]
15. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer.
Goff BA; Shy K; Greer BE; Muntz HG; Skelly M; Gown AM
Eur J Gynaecol Oncol; 1996; 17(6):487-92. PubMed ID: 8971524
[TBL] [Abstract][Full Text] [Related]
16. Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma.
Dergham ST; Dugan MC; Arlauskas P; Du W; Vaitkevicius VK; Crissman JD; Sarkar FH
Int J Pancreatol; 1997 Jun; 21(3):225-34. PubMed ID: 9322121
[TBL] [Abstract][Full Text] [Related]
17. Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan.
Tsai YS; Tzai TS; Chow NH; Yang WH; Tong YC; Lin JS; Chang CC; Cheng HL; Lin YM
Urol Int; 2003; 71(3):262-70. PubMed ID: 14512646
[TBL] [Abstract][Full Text] [Related]
18. HER 2/neu protein expression in gastric cancer is associated with poor survival.
Xie SD; Xu CY; Shen JG; Jiang ZN; Shen JY; Wang LB
Mol Med Rep; 2009; 2(6):943-6. PubMed ID: 21475925
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma.
Movagharnejad K; Sharbatdaran M; Sheffaee S; Kashifard M; Sedaghat S
Int J Mol Cell Med; 2013; 2(4):199-203. PubMed ID: 24551813
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
